Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study
Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.
Main Inclusion Criteria:
Main Exclusion Criteria:
Neusiedl/See, 7100, Austria
Ontario, L4C3Y1, Canada
Sainte-Foy, Quebec, G1V4G5, Canada
Saskatoon SK, S7N 0W8, Canada
Winnipeg MB, R2K 3S8, Canada
Cisanello (PI), 56100, Italy
Fuentesnuevas, Ponferrada (LeĂ³n), 24411, Spain
MatarĂ³, Barcelona, 8303, Spain
Tarrasa (Barcelona), 8221, Spain
Chesterfield Derbyshire, S40 4TF, United Kingdom
East Sussex, TN39 5HE, United Kingdom
Middlessex, HA6 2RN, United Kingdom